How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

Liquid biopsy based early breast cancer detection

Organization name

PROvendis GmbH

Profile

Invention

Early breast cancer detection, most favorably in a pre-cancerous (in situ) state is critical for the course of the disease and its outcome.

Currently, mammography screening is the standard method of medical prevention. However, the compliance among women invited for mammography is low ranging from merely 20 to 89 percent depending on country and age group. Similar to colorectal cancer prevention by coloscopy, a much easier and less stressful examination method might find stronger compliance.

Researchers of the University Medical Center of Aachen have identified biomarkers, which are suitable for detection of early breast cancer and its precancerous stages in blood, based on the measurement of both grade and intensity of CpG promoter methylation of i.e. the genes SPAG6, NKX2-6 and PER1. A combination of two genes or the inclusion of other genes (e.g. DKK3 or ITIH5) may also apply. It is very likely that a blood-based test would increase compliance of women to medical prevention programs of breast cancer. In addition, this concept may allow to broaden prevention to elderly women (>70 years) who currently are not invited to mammography screening.

Commercial Opportunities

In April 2016, a blood-based early detection system for colon cancer has been approved by the FDA. The inventive biomarkers could be applied in an analogous way for breast cancer detection. Both tests have similar sensitivity and specificity, suggesting a good chance of the present test also to be approved in a similar setting. Notably, a key argument for the approval by the FDA has been the likelihood of increased acceptance by the relevant population thus reinforcing screening participation.

On behalf of the University of Aachen (RWTH Aachen), PROvendis offers a patent license as well as a research collaboration with licensing option.

Current Status  

The initial study included blood samples of 130 age-matched donors that comprised early breast cancer stages (T1N0M0), non-invasive DCIS (ductal carcinoma in situ) and healthy controls. The methylation intensity was measured by means of pyrosequencing. Currently, an additional 400 blood samples are being analyzed. In parallel, the inventors are establishing a NGS based protocol for methylation detection to improve the technical sensitivity. In case of interest we are pleased to inform you about the patent status.

An invention of the University Medical Center of Aachen (UKA).

Competitive Advantages

  • Blood-based easy to perform pre-screen to current standard mammography
  • Likelihood of much higher compliance of eligible women and consequently increasing screening participation

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries